Agios Pharmaceuticals盘前涨近12%，获美国FDA批准扩大血液病药物的使用范围

Core Viewpoint - Agios Pharmaceuticals' stock rose nearly 12% to $27.5 following FDA approval to expand the use of its blood disorder drug, mitapivat, for treating anemia in adult patients with α- or β-thalassemia [1] Group 1 - Agios Pharmaceuticals is a U.S. pharmaceutical company focused on developing treatments for blood disorders [1] - The drug mitapivat, marketed under the brand name Aqvesme, is currently undergoing testing for its efficacy in treating anemia associated with thalassemia [1] - The FDA's approval marks a significant milestone for Agios Pharmaceuticals, potentially increasing the drug's market reach and sales [1]